The gastric cholecystokinin-B/gastrin receptor (CCK-BR) is a key regulator of enterochromaffin-like cell function and proliferation. Over the last decade, a number of small non-peptide CCK-BR "antagonists" have been discovered. Here, we demonstrate that some of these non-peptide ligands in fact possess significant ability to activate the human CCK-BR, and are, therefore, more properly categorized as partial agonists. When tested in COS-7 cells transiently expressing the recombinant human CCK-BR, saturating concentrations of the small "peptoid" ligands PD 135,158 and PD 136,450 stimulated inositol phosphate formation to 23 and 43 percent, respectively, of the maximum response induced by a considerably larger endogenous peptide agonist, cholecystokinin octapeptide. In contrast, the benzodiazepine-derived CCK-BR ligand, YM022, acted as a "true" high-affinity antagonist of cholecystokinin-induced inositol phosphate formation (pA2 = 9.69). Consistent with recent findings in animal experiments, our data reveal that small synthetic ligands have the potential to function as either CCK-BR agonists or antagonists. These dual properties of synthetic molecules must be considered when evaluating candidate drugs for human disease.
INTRODUCTION
The cholecystokinin-B/gastrin receptor (CCK-BR)b is a seven transmembrane domain protein that modulates multiple functions in both the gastrointestinal tract and the brain [1, 2] . In the stomach, the CCK-BR has been well established to stimulate gastric acid secretion and mucosal cell growth [3, 4] . In particular, there is strong evidence suggesting that this receptor can induce the proliferation of enterochromaffin-like cells [5] . In the brain, the CCK-BR has been implicated in triggering anxiety attacks and may also modulate the perception of pain [6] [7] [8] [9] .
The CCK-BR is endogenously activated by structurally related endogenous peptide hormones and neurotransmitters, including the heptadecapeptide gastrin (G-17) and the octapeptide cholecystokinin (CCK-8). These peptides bind to the CCK-BR with affinities in the subnanomolar range and lead to the activation of phospholipase-C as a major second messenger pathway. Phospholipase-C, in turn, initiates the breakdown of membrane phospholipids to inositol phosphate metabolites and the subsequent release of intracellular Ca2+ as early signal transduction events [2, 4] .
High affinity binding of endogenous peptide ligands to the CCK-BR is mimicked by considerably smaller synthetic molecules, which have been developed in an attempt to generate clinically useful CCK-BR antagonists. Such compounds include (i) "peptoid" derivatives that retain minimal structural features of the endogenous peptide agonists [10, a'To whom all correspondence should be addressed: Martin Beinborn 11], and (ii) a chemically different class of molecules with a common benzodiazepine-like backbone [12, 13] . Interestingly, we have recently discovered that these putative non-peptide antagonists occupy a ligand "pocket" within the transmembrane domains of the CCK-BR, similar to that described for biogenic amine receptors [14] .
Given this considerable overlap of binding determinants, we speculated whether small synthetic CCK-BR ligands might have similar agonist potential as biogenic amines of similar size [15] . In fact, this hypothesis is supported by recent reports that "peptoid" compounds may act as partial agonists of the CCK-BR in vivo, with the ability to stimulate gastric acid secretion and ECL cell activation [16, 17] . In contrast, other investigators have been unable to detect any intrinsic activity of "peptoids" in the rat [18] [19] [20] [21] [22] . Measurement of inositol phosphate accumulation Forty-eight hours after transfection, COS-7 cells were seeded into 6-well plates (3 x 105/well) (Nunc). The cells were then pre-labelled overnight with 3 mCi/ml 3H-myo-inositol in serum-free Dulbecco's modified Eagle medium. To assess total inositol phosphate formation, the media were replaced with phosphate-buffered saline containing 10 mM LiCl, and cells were incubated with the respective ligands for 30 min at 37°C. Inositol metabolites were extracted with methanol/chloroform; the upper phase was analyzed for inositol phosphates by strong anion exchange chromatography [23] . Inositol phosphate production was expressed as the percent of total cellular tritium content incorporated during an overnight exposure to 3H-myo-inositol.
RESULTS AND DISCUSSION
We have previously demonstrated that the recombinant human CCK-BR, when transiently expressed in COS-7 cells, triggers CCK-8 induced inositol phosphate production and Ca2+ release from intracellular stores [1] . These in vitro findings are consistent with the well established coupling of the native CCK-BR to activation of phospholipase-C in gastric parietal cells [24] [25] [26] (Figure iB) , indicating that the recombinant CCK-BR is efficiently coupled to intracellular signaling in COS-7 cells. Therefore, this in vitro system provides high functional sensitivity and can be utilized to detect intrinsic agonist properties of CCK-BR ligands.
The small synthetic CCK-BR ligands analyzed in this study included the "peptoid" compounds, PD 135,158 and PD 136,450 [27, 28] , as well as three benzodiazepine-based ligands, L-364,718, L-365,260, and YM022 [29-3 1] . All of these compounds were able to compete with the peptide radioligand, 1251-CCK-8, for binding to the CCK-BR (Figure 2 ).
Given the close correlation between receptor occupation and induction of intracellular signaling (see above), we used the data in Figure 2 to predict which ligand concentrations are likely to result in full receptor activation. In general, we tested the ability of individual compounds to trigger inositol phosphate production using a single ligand concentration which was at least 100-fold higher than required for 50 percent receptor occupation (indicated by the corresponding IC50 values in radioligand competition experiments, see legend of Figure 2 ). As an exception, the tested concentration of L-364,718 was limited to 5 ,uM Figure 1A) , when plotted as a function of CCK-8 concentration, follow a curve which is virtually superimposable with curves describing CCK-8 dependent inositol phosphate formation or receptor occupation. Receptor occupation was calculated from 1251-CCK-8 competition binding studies with unlabelled CCK-8 (see Figure 2 ). All data in Figure 1 show the results of a single experiment with cells transfected on the same day, and are consistent with several replicate experiments where receptor binding and function were assessed on different days (e.g., data in Figures 2-4) . Figure 3 and IC50 values in Figure 2 ), again confirming the close correlation of receptor binding and functional parameters in our in vitro system. Interestingly, both tested "peptoid" ligands have been recently reported to act as partial agonists in the rat and have been demonstrated by in vivo experiments to stimulate gastric acid secretion [17] and the activity of histidine decarboxylase as a marker of mucosal ECL cell density [16] . In contrast, other experiments suggested that PD 136,450 has no appreciable intrinsic activity in the rat and acts as a true antagonist of gastric acid secretion [19, 21] and of gastrin-induced mucosal proliferation [20] . Furthermore, it has been reported that "peptoid" compounds including PD 136,450 and PD 135,158 antagonized CCK-BR mediated electrophysiological responses in the rat ventromedial hypothalamus [18] . Together, these apparently contradictory results illustrate the difficulty in classifying CCK-BR ligands using relatively complex native tissues or in vivo models, where druginduced effects may depend on multiple interacting mechanisms and can be easily biased by the choice of experimental conditions. Moreover, it must be also considered that ligand function as an antagonist or as a partial agonist may heavily depend on the cellular microenvironment where native or recombinant receptors are expressed (e.g., in gastric parietal vs. nerve cells) and is also expected to be a function of receptor densities (which may differ even between rat strains). At the receptor level, we have recently shown that differences in drug efficacy can also result from minimal species differences in the amino acid sequence of their respective CCK-BRs [32] . Considering these limitations of characterizing drug pharmacology in animal experiments, it is important to verify the functional 4 PD 136,450
Peptoid concentration, log (M) properties of candidate drugs in a less complex model system that eliminates a large number of these confounding variables. In our test system, we have obtained unambiguous evidence that "peptoid" compounds can, in principle, activate the human CCK-BR isoform. Again, it is important to note that this finding, in itself, is not necessarily predictive of overall in vivo function but rather reflects properties of "peptoid" ligands, which may actually apply only to certain native cell types. The anticipated diversity in ligand efficacy is exemplified by a recent report where the recombinant human CCK-BR was expressed in CHO (instead of COS-7) cells, and the "peptoid" compound PD 135, 158 appeared to act as a "true" antagonist (rather than as a partial agonist) [33] . In any case, knowledge of the full spectrum of intrinsic activities to be anticipated will be a helpful guideline for evaluating the pharmacology of "peptoid" drugs in humans. In contrast to "peptoid" molecules, all three benzodiazepine-derived compounds which were tested had very little, if any, ability to activate the human CCK-BR ( Figure  4A ). These compounds represent three generations of molecules in a promising series of putative CCK receptor antagonists which have been developed over the past decade.
L-364,718, the derivative with lowest affinity at the human CCK-BR (Figure 1 ), was one of the first synthetically generated high affinity ligands for any peptide hormone receptor (although it was targeted at the CCK-A receptor subtype, rather than the CCK-BR) [12, 29] . A derivative of this molecule, L-365,260, is considered the prototype CCK-BR non-peptide antagonist and was the first synthetic ligand for this receptor with affinity in the nanomolar range [30] . Recent YM022 concentration, log (M) Figure 4B . the human CCK-BR ( Figure 2 ) and its apparent lack of intrinsic activity ( Figure 4A ), we were able to verify that YM022 acts as a high affinity antagonist and completely blocks CCK-8 induced inositol phosphate formation ( Figure 4B ). As expected for a competitive antagonist, the pA2 value of YM022 (reflecting its functional affinity) was close to its IC50 value in competition binding experiments (compare legends of Figures 2 and 4B) . Although, by these experiments, benzodiazepine-based ligands appear to act as "true" antagonists and seem to have generally different functional properties than "peptoid" ligands, we have evidence that this distinction does not always apply. Preliminary data suggest that even benzodiazepine-based CCK-BR ligands have inherent agonist potential, which can be optimized by minor chemical modifications of these molecules [34] . Furthermore, ligands with similar benzodiazepine-like structure have recently been shown to act as partial or even full agonists of the CCK-A receptor subtype, both in vivo and in vitro [35] . With these precedents, it is likely that presently known non-peptide "antagonists" for peptide hormone receptors, due to their inherent potential, can be systematically modified to generate a broad range of clinically useful agonist drugs. Equally important, these intriguing findings should raise the awareness that apparent non-peptide "antagonists" for peptide hormone receptors could possess residual intrinsic activity which may result in unexpected, and possibly adverse, biological effects in the context of certain human diseases.
